Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

24. Dezember 2025 bis 1. Januar 2026: Die Deutsche Nationalbibliothek bleibt an beiden Standorten geschlossen. Bestellte Medien werden am 2. Januar 2026 bereitgestellt. // 24 December 2025 to 1 January 2026: The German National Library will be closed at both locations. Ordered media will be made available on 2 January 2026.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

91 - 100 von 146

	91	Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study Enthalten in BioDrugs Bd. 32, 20.7.2018, Nr. 4, date:8.2018: 367-375
	92	Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC Enthalten in Analytical and bioanalytical chemistry Bd. 414, 27.7.2022, Nr. 23, date:9.2022: 6761-6769
	93	Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018 Enthalten in Advances in therapy Bd. 39, 30.8.2022, Nr. 11, date:11.2022: 5300
	94	Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review Enthalten in Advances in therapy Bd. 38, 19.7.2021, Nr. 8, date:8.2021: 4602
	95	Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis Enthalten in Advances in therapy Bd. 36, 30.5.2019, Nr. 8, date:8.2019: 2086-2095
	96	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis Enthalten in BioDrugs Bd. 35, 11.5.2021, Nr. 4, date:7.2021: 469-471
	97	Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018 Enthalten in Advances in therapy Bd. 39, 23.6.2022, Nr. 8, date:8.2022: 3711-3734
	98	Discrepancies Between the Labels of Originator and Generic Pharmaceutical Products: Implications for Patient Safety Enthalten in Drugs - real world outcomes Bd. 7, 22.4.2020, Nr. 2, date:6.2020: 131-139
	99	Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis Enthalten in Arthritis Research & Therapy Bd. 27, 17.7.2025, Nr. 1, date:12.2025: 1-7
	100	Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review Enthalten in Advances in therapy Bd. 36, 5.6.2019, Nr. 8, date:8.2019: 1851-1877